Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.

Abstract: The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).

Abstract: Each node in a subset of graph nodes has an associated label value indicating a characteristic of the corresponding item. Matrix data and graph label data are stored. The matrix data defines a matrix representing the graph. The graph label data defines a graph label vector indicating label values associated with nodes of the graph. For at least one set of nodes, test label data is generated defining a test label vector. A propagation function is defined, comprising a set of basis functions, having respective coefficients. The coefficients are calculated which minimize a difference function dependent on difference between the graph label vector and a result of applying the propagation function to the test label vector for said at least one set. New label values are calculated for nodes in K by applying the propagation function with the calculated coefficients to the graph label vector, thereby propagating labels.

Abstract: An example medical device is disclosed as an expandable stent. The stent includes a tubular scaffold having an inner surface, an outer surface, and a lumen extending therein. The expandable stent also includes a liner disposed within the lumen of the tubular scaffold. Further, the liner is radially spaced from a medial region of the tubular scaffold to define a tissue ingrowth region along an uncovered portion of the medial region. Additionally, the liner extending along the tissue ingrowth region is configured to limit the amount of tissue ingrowth along the medial region of the scaffold.

Abstract: A cassette sequence for the transformation of a host cell includes at least: a first nucleotide sequence encoding a peptide or protein of interest to be produced by the host cell. The first sequence is linked to a second nucleotide sequence providing resistance to a toxin or encoding an antitoxin peptide to the toxin. The nucleotide sequences are organized in such a way that production of the peptide encoded by the second nucleotide sequence(s) is translationally coupled to production of the peptide encoded by the first nucleotide sequence.

Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.

Abstract: A calixarene directly grafted onto the surface of a material, a related grafting process, and certain calixarene intermediates useful for carrying out the grafting process.

Abstract: A method for manufacturing an ?+? Ti-6Al-4V alloy includes providing a near-net shape part made of an ?+? Ti-6Al-4V alloy, The part is heat treated in the ?+? field between 875 and 920° C. The heat treated part is water quenched to transform the ? phase into ?? martensite. There is no further heat treatment after the quenching step.

Abstract: An assaying kit is for pre-transfusion blood group matching between two blood samples. The kit includes at least two assemblies (101,201) corresponding to the first and the second blood sample, each assembly has at least two test units (1). Each test unit (1) includes a reagent containing an antigen present on erythrocytes or an antibody able to bind to an antigen present on erythrocytes. Each test unit (1) also includes a membrane (2) permeable to free erythrocytes (6) and impermeable to hemagglutinated erythrocytes. The antibody contained in the first test unit for both the first assembly (101) and the second assembly (201) corresponds to a first blood group and the antibody contained in the second test units for both the first assembly (101) and the second assembly (201) corresponds to a second blood group.

Abstract: The present application provides a pharmaceutical formulation comprising a folate receptor (FR)-targeting antineoplastic substance or composition, wherein the pharmaceutical formulation is configured for administration by inhalation, wherein the FR-targeting antineoplastic substance or composition is comprised in a nanoparticle and wherein the nanoparticles are comprised in microparticles, and its use in the treatment of a proliferative disease affecting at least part of the respiratory tract. The present application further provides a pharmaceutical formulation comprising an antineoplastic agent and a FR-targeting excipient, for use in the treatment of a proliferative disease affecting at least part of the respiratory tract.

Abstract: The invention relates to in vitro methods for differentiating mammalian pluripotent stem cells into cells displaying a neuronal phenotype, more particularly into cortical-type neurons including inter alia pyramidal neurons and cortical inhibitory interneurons. The invention further encompasses so-obtained neuronal cells and cell population, compositions comprising such, and further uses of said neuronal cells and cell population.

Abstract: An example medical device is disclosed as an expandable stent. The stent includes a tubular scaffold having an inner surface, an outer surface, and a lumen extending therein. The expandable stent also includes a liner disposed within the lumen of the tubular scaffold. Further, the liner is radially spaced from a medial region of the tubular scaffold to define a tissue ingrowth region along an uncovered portion of the medial region. Additionally, the liner extending along the tissue ingrowth region is configured to limit the amount of tissue ingrowth along the medial region of the scaffold.

Abstract: Described herein is a multi-dimensional kineticardiography device (300) which comprises a sensor (320) having three accelerometer/gyroscope modules (320X, 320Y, 320Z) mounted in a support which positions it at the centre of mass of a subject whose cardiac function is to be measured. The sensor (320) outputs six degrees of freedom data as linear acceleration along and rotational or angular velocity about x-, y- and z-axes. The sensor (320) is connected to a processor (335) for transmitting the kineticardiography data obtained from the sensor (320) and the electrocardiography data to a mobile computing platform (330), via Bluetooth (350), for further processing and display. An electrocardiography data chip (370) is also present for digitising the electrocardiography data for further processing.

Abstract: Force transducer (10) include two structural members (11, 12) spaced apart to define a gap (101) and being linked to each other. Optical fibers (13) are to the members and are freely suspended in the gap. The optical fibers are configured to provide a change in a detectable optical property responsive to a change in relative position between the two members in one or more predetermined degrees of freedom. Each of the optical fibers (13) is fixed to both structural members and continuous between the members to link the two structural members to each other. The optical fibers are substantially the only structure forming a link between the two structural members (11, 12), such that the arrangement of the optical fibers defines substantially the stiffness of the link between the two structural members in the one or more predetermined degrees of freedom, which stiffness is mainly, such as for at least 95%, determined by the optical fibers.

Abstract: A method of selective catheterism of in a network of conduits of an anatomical structure including inserting a flexible distal end of a guide for catheterism through the network of conduits. An appendage is attached on the distal end of the guide, the appendage includes a channel extending along a longitudinal axis of the guide. A catheter is slid along the catheter until a distal face of the catheter surrounding the guide engages a proximal surface of the appendage. A force oriented in a distal direction is exerted with the catheter on the appendage, which disengages the appendage from the distal end of the guide within the network of conduits. Navigation through the network of conduits is continued with the flexible distal end of the guide once the appendage is removed.

Abstract: The liquid steel slag (2) is poured in at least four successive layers (6-8), comprising a lowermost layer (6), an uppermost layer (7) and at least two intermediate layers (8), in a reservoir (3) and the layers of liquid steel slag are allowed to solidify. After having applied the uppermost layer (7), the solidified steel slag is cooled down more quickly by means of water. The average temperature of each of the intermediate layers (8) is kept at least until the start of the water cooling step, and this for at least one hour, above a minimum temperature which is equal to or higher than the temperature at which ?-dicalcium silicate is formed. In this way, more crystalline phases different from dicalcium silicates are formed so that the formation of fines by the transition of ? into ?-dicalcium silicates can be considerably reduced. A glassy material and/or a phosphorus containing compound is preferably added to the liquid slag to further reduce the formation of fines.

Abstract: The present invention provides new methods of treatment of lentiviral infections, more particularly to treat latent retroviral HIV infections, present in cells of the infected subject, based on the re-activation of said viruses. The invention uses a combination therapy using several agents that result in strong re-activation of the latent HIV-virus that could destroy the infected cells and elicite an immune response in the subject. This could present further spread of the infection, with the ultimate aim to eradicate the virus completely in said subject.

Abstract: The present invention provides a method and a kit for detecting a S. pneumoniae nucleic acid in a sample. The method comprises the steps of isolating said nucleic acid and detecting hybridization between the S. pneumoniae nucleic acid and a labeled probe, wherein the detection of hybridization comprises detecting a change in signal from the labeled probe during or after hybridization relative to the labeled probe signal before hybridization. The method of the present invention is characterized in that said nucleic acid is a ribonucleic acid, which isolation comprises the addition of acidic phenol to said sample and the purification of said ribonucleic acid.

Abstract: A method for detecting and measuring the amount of an ionic impurity, notably formula (A) and/or formula (B) in a liquid sample, notably water, comprises: Introducing the liquid sample through a liquid inlet into a measurement cell, notably an optical cavity of an optical spectrometer; Causing vaporisation of the liquid sample by maintaining the pressure in the measurement cell below the saturated vapour pressure of the liquid sample; Causing the formation of gas-phase reaction product(s) of the ionic impurity; Measuring the amount of the gas-phase reaction product(s) of the ionic impurity in the measurement cell.

Abstract: A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.